Max Nisen, Columnist

Vulnerable Drugmakers Can't Shrug Off the FDA

Investors are ignoring the latest sign of a pricing crackdown.

June 29, 2017 at 6:00 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

FDA Commissioner-designate Scott Gottlieb testifies during a Senate Health, Education, Labor and Pensions Committee hearing on April 5, 2017 at on Capitol Hill in Washington, D.C.
Photographer: Zach Gibson

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

The new FDA commissioner's tough tone on drug pricing isn't just bluff.

In an effort to call attention to drugs that could stand a little price-lowering competition, FDA chief Scott Gottlieb this week released a list of hundreds of medicines that don't have market rivals, including old drugs without patent protection that still have no generic alternatives.